Insulin degludec Subcutaneous and Targretin (Bexarotene (Systemic))
Determining the interaction of Insulin degludec Subcutaneous and Targretin (Bexarotene (Systemic)) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using bexarotene together with insulin or certain other diabetes medications may increase the risk of hypoglycemia, or low blood sugar. Symptoms of low blood sugar include headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, sweating, and fast or pounding heartbeats. You may need a dose adjustment or more frequent monitoring of your blood sugar to safely use both medications. Talk to your doctor or pharmacist if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: The hypoglycemic effect of insulin and certain other antidiabetic agents (e.g., sulfonylureas, thiazolidinediones) may theoretically be potentiated by bexarotene. Bexarotene may increase the risk of hypoglycemia by enhancing insulin sensitivity and/or stimulating insulin secretion. Clinical hypoglycemia has not been reported during use of bexarotene as monotherapy.
MANAGEMENT: Close monitoring for the development of hypoglycemia is recommended if bexarotene is coadministered with insulin or another antidiabetic agent, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic or insulin dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when bexarotene is withdrawn.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."
- Agencia EspaƱola de Medicamentos y Productos Sanitarios Healthcare "Centro de informaciĆ³n online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):
Generic Name: insulin degludec
Brand name: Tresiba, Tresiba FlexTouch
Synonyms: Insulin degludec, Insulin Degludec
Generic Name: bexarotene
Brand name: Targretin
Synonyms: Bexarotene, Bexarotene (Systemic)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin degludec Subcutaneous-Targretin (Bexarotene (Topical))
- Insulin degludec Subcutaneous-Targretin Gel
- Insulin degludec Subcutaneous-Targretin topical
- Insulin degludec Subcutaneous-Tarina 24 Fe
- Insulin degludec Subcutaneous-Tarina Fe 1/20
- Insulin degludec Subcutaneous-Tarka
- Targretin (Bexarotene (Systemic))-Insulin detemir
- Targretin (Bexarotene (Systemic))-Insulin Detemir (Cartridges and Prefilled Syringes)
- Targretin (Bexarotene (Systemic))-Insulin Detemir (Vials)
- Targretin (Bexarotene (Systemic))-Insulin detemir Subcutaneous
- Targretin (Bexarotene (Systemic))-Insulin glargine
- Targretin (Bexarotene (Systemic))-Insulin Glargine (U-100) Cartridge Systems and Pens